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The dimethyhydrazine (DMH) or azoxymethane (AOM) model is a well-established, well-appreciated, and widely used model of
experimentalcoloncarcinogenesis.Ithasmanymorphologicalaswellasmolecularsimilaritiestohumansporadiccolorectalcancer
(CC),whicharesummarizedanddiscussedinthispaper.Inaddition,thepapercombinespresentknowledgeofmorphologicaland
molecularfeaturesinthemultistepdevelopmentofCCrecognizedintheDMH/AOMratmodel.Thisunderstandingisnecessaryin
order to accurately identify and interpret alterations that occur in the colonic mucosa when evaluating natural or pharmacological
compounds in DMH/AOM rat colon carcinogenesis. The DMH/AOM model provides a wide range of options for investigating
various initiating and environmental factors, the role of speciﬁc dietary and genetic factors, and therapeutic options in CC. The
limitations of this model and suggested areas in which more research is required are also discussed.
1.Introduction
Colorectalcancer(CC)is one ofthe leading causesofcancer-
related morbidity and mortality in humans in western
developed countries [1]. In recent years, increasing attention
has been paid to environmental and food components, with
the hope of identifying its preventive or carcinogenic eﬀects
[2, 3]. Much eﬀort has been dedicated to a search for natural
or pharmacological preventive agents, which would block or
attenuate CC process [4, 5].
There are several experimental models of CC, providing
a wide range of options for investigating various initiating
and environmental factors, the role of speciﬁc dietary and
geneticfactors,andtherapeuticoptionsinCC.Thesemodels,
which can be broadly divided into induced and transgenic
animal models, vary in their suitability for investigating
eachofthesefactors.Homologousrecombinationofrandom
chemically induced mutagenesis has been used to generate
as e r i e so fA P C( + / −) mice that exhibit mutation in
codons 474, 716, 850, or 1638 of the APC tumour sup-
pressor gene and encode a truncated gene product. Similar
recombination approaches have also generated a mouse
model with a mutation in the DNA mismatch repair genes.
Mlh1 (+/−), Mlh1 (−/−), Msh6 (+/−), and Msh6 (−/−)
mice exhibit accelerated small intestinal carcinogenesis.
These animal models have been generated to study familial
adenomatous polyposis (FAP) and hereditary nonpolyposis
colorectal cancer (HNPCC) syndromes and are described
elsewhere [6]. Among chemically induced animal models,
1,2 dimethylhydrazine (DMH) and azoxymethane (AOM)
animal models are most frequently used [4, 7–9]. Induction
of colon cancer by other chemical carcinogens, such as
nitrosamines or heterocyclic amines is less frequently used
[10–12], because DMH and AOM (DMH/AOM) are less
expensive, more potent and more convenient to use [7, 9].
The DMH/AOM model of colon carcinogenesis is a valid,
well-appreciated, and widely used model of experimental
colon carcinogenesis. It shares many similarities to human
sporadic CC, including similarities in the response to some
promotional and preventive agents [4]. Today, it is a widely
used model for the evaluation of environmental, dietary, and
chemopreventive agents in the colon cancer process. It is also2 Journal of Biomedicine and Biotechnology
usedtostudymorphologicandmolecularmechanismsofthe
multistage development of colon cancer in order to elucidate
new targets for chemoprevention [12, 13].
A number of excellent reviews on animal models of
colon carcinogenesis [6, 12], including chemically induced
carcinogenesis [7, 13, 14], have recently been published.
VariousaspectsoftheapplicabilityoftheDMH/AOManimal
model are demonstrated in these papers. However, in order
accurately to identify and interpret alterations that occur
in the colonic mucosa when assessing natural or pharma-
cological compounds in an animal model, understanding
both the morphologic and molecular development of the
CC process in this model is required. This paper, therefore,
summarizes the present knowledge of morphological and
molecular features in multistep development of CC in the
DMH/AOMratmodelanditssimilaritiestohumansporadic
CC. In addition, features and limitations of this model and
suggested areas in which more research is required are also
discussed.
2. Induction of DMH/AOM Colon
Carcinogenesis
DMH and its metabolite AOM are widely used agents for the
induction of colorectal carcinogenesis in rodents. DMH is
metabolically activated in the liver by a series of reactions
through intermediates AOM and methylazoxymethanol
(MAM) to the ultimate carcinogenic metabolite, highly reac-
tive methyldiazonium ion [15]. MAM can be excreted into
the bile and transported to the colon (the development of
smallintestinaltumoursdistaltotheentranceofthebileduct
into the intestine is ascribed to this path) or enter directly
into epithelial cells of the colon from blood circulation [15].
Somestudieshavealsodemonstratedthatratcolonepithelial
cells are capable of metabolizing DMH into the carcinogenic
metabolite without previous metabolism by other tissues or
colon bacteria [16,17].Theultimatecarcinogenicmetabolite
of DMH is responsible for methylation of the DNA bases of
various organs, including epithelial cells in the proliferative
compartment of the crypts, which result in a great loss of
colonic cells by apoptosis, an increase in proliferation, and
an apparent increase in mutations of colonic epithelial cells
[18].
However, DMH/AOM are highly speciﬁc carcinogens
that induce colorectal tumours in a dose-dependent manner
[19]. Various rat and mouse strains diﬀer in susceptibil-
ity to these carcinogens [12, 20]. The susceptibility for
DMH/AOM-induced colorectal carcinogenesis is also sex
[21] and age dependent [22, 23]. Most commonly, 6 weeks
old male F344, Wistar and Sprague-Dawely rats are used
[7, 8]. Colon carcinogenesis is usually induced by two s/c
applications of DMH (150mg/kg) or AOM (15mg/kg) given
one week apart. Using these protocols, animals are scored
for intermediate biomarkers of colon carcinogenesis, termed
aberrant crypt foci (ACF), 8–12 weeks after the application
(short-term study) or for the number of colonic tumours 40
weeks later (long-term study). Chemopreventive treatment
can begin before exposure to the carcinogen and during
the initiation phase, during the promotion or progression
phase, or through both phases. These protocols are used
to assess the promotional or protective eﬀects of the tested
factor and when followed closely provide data that are quite
reproducible (protocol explained in detail by Femia and
Caderni [7]a n dB i r d[ 9]).
Nevertheless, tumour outcome depends on the total
amount of carcinogen administered and the latency period.
In long-term studies, therefore, DMH is frequently admin-
istered weekly for 15 weeks in a relatively low concentration
(20mg/kg). Repeated injections of carcinogen are evident at
a later stage of cancer development and not in the stage of
preneoplastic lesions, that is, ACF [24] and result in higher
tumourincidenceandmultiplicitythanfollowingoneortwo
injections of a colon carcinogen [19, 24].
3. Histopathological Nomenclatureof
Colorectal EpithelialLesions
DMH/AOM colon carcinogenesis is a multistep process with
morphological and histological features similar to those seen
in human sporadic colon carcinogenesis [25, 26]. It is widely
accepted today that the adenoma to carcinoma sequence is
characterized by recognizable histological changes that start
with dysplastic aberrant crypts or intraepithelial neoplasia
(IEN) [27, 28]. These lesions then have the potential to
progress to advanced adenomas, which have a signiﬁcant
potential to transform into adenocarcinomas [26].
3.1. Intraepithelial Lesions. The ﬁrst lesions in the multistep
development of CC cannot be seen grossly. They can be
identiﬁed in histological sections of colon mucosa after
careful histological examination as hyperplastic or dysplastic
epitheliallesions[29]oronthesurfaceofwholemountcolon
under low-magniﬁcation stereomicroscope as ACF [24, 25]
or mucin depleted foci (MDF) [28, 30]. It is important to
bear in mind that visualization and identiﬁcation of ACF
or MDF on whole mount colon does not yield speciﬁc
information on the histological features of these lesions. The
structural and cytological features of ACF or MDF can be
recognized or conﬁrmed only after histological examination.
Nevertheless, in order better to understand the histological
background of ACF and MDA (which are described in the
next section) as well as molecular alterations recognized and
described at diﬀerent stages of colon carcinogenesis, we will
brieﬂy summarize the histological criteria and classiﬁcation
of colorectal epithelial lesions in rodents, which share many
similarities with human pathology [26, 29].
3.1.1. Hyperplastic Intraepithelial Lesions. Hyperplastic
epithelial lesions are composed of a mixture of goblet and
absorptive cells, with enlarged or sometimes crowded nuclei
without stratiﬁcation. Mitotic ﬁgures are limited to the
lower two thirds of the crypts and are never observed on the
surface of crypts. Nuclei are basally located, ovoid or round,
with occasional visible nucleoli and usually uniformly
dark. The luminal opening of crypts is slightly elevated
from the surrounding normal mucosa and the crypts areJournal of Biomedicine and Biotechnology 3
elongated and occasionally branching, with partial mucin
depletion [29]. It is worth mentioning that hyperplastic
epithelium has never been observed in colonic tumours
of the DMH/AOM rat model. It has only been found in
intraepithelial lesions composed of a various number of
crypts. The role of hyperplastic aberrant crypts in the
process of colon carcinogenesis in DMH/AOM models is not
clear and is a matter of debate and further investigation.
3.1.2. Intraepithelial Neoplasia/Dysplasia. Inraepithelial neo-
plasia is a histological term for dysplastic lesions in the
epithelial layer of colon mucosa that cannot be identiﬁed
macroscopically but only after careful histological exam-
ination. The presence of dysplasia is regarded as early
histopathological changes in the precursor lesions of colon
cancer. The word dysplasia is used to describe structural
and cytological alterations in the epithelium that predispose
an organ to cancer development. IEN is synonymous with
the terms atypical hyperplasia, microadenoma, carcinoma
in situ, and dysplasia. Depending on the cytological and
architectural features, IEN is classiﬁed as low grade or high
grade. The diﬀerential criteria involve hypercelularity with
enlarged, hyperchromatic nuclei, varying degrees of nuclear
stratiﬁcation,lossofpolarity,highnuclear/cytoplasmicratio,
nuclear crowding, increased mitotic index, and decreased
mucine excretion [29].
3.2. Tumours. Pathological changes that can be seen macro-
scopically on the surface of colon mucosa as pedunculated
or broad-based, slightly elevated, ﬂat, or depressed (sessile
or nonpolypoid) masses/lesions are called tumours. The
incidence of colon tumours is the most reliable endpoint
for evaluation of the chemopreventive eﬀects of substances.
Furtherhistologicalexaminationisrequiredtodeterminethe
malignant or benign character of tumours.
3.2.1. Adenomas. Tumours conﬁned to the mucosa are
benign neoplasms that are called adenomas. On the basis
of the histologic type, adenomas can be tubular (when
more than 75% of the adenoma is composed of branching
tubules),villous(morethan75%ofadenomaiscomposedof
villous structures), or tubulovillous (25%–75% of adenoma
composed of both tubular and villous structures). Depend-
ing on the degree of dysplasia on the most severely dysplastic
area of each tumour, adenomas are graded as low or high
[29].
3.2.2. Adenocarcinomas. Tumours that penetrate through
the muscularis mucosa are malignant lesions, histologically
denoted adenocarcinomas (well, moderately, or poorly dif-
ferentiated). Based on the histological type, they are further
classiﬁed into tubular, tubulovillous, or villous adenocarci-
nomas (as with adenomas), mucinous adenocarcinomas (if
more than 50% of the lesion is composed of extracellular
mucin and signet-ring cell can be present), signet-ring
cell adenocarcinomas (if more than 50% of tumour cells
with prominent intracytoplasmic mucin are present), and
undiﬀerentiated carcinoma (if no glandular structure is
present) [29].
4. Biomarkers of Colon Carcinogenesis
In the past, assessment of chemopreventive substances was
based on the incidence of tumours. Since the development
of tumours is a relatively lengthy process, taking around
6–8 months to develop in the DMH/AOM rat model,
preneoplastic lesions can be used as biomarkers for assessing
the risk of developing colon cancer or for identifying
modulators of colon carcinogenesis in short-term studies
[9]. The use of preneoplastic lesions as biomarkers was not
possible until 1987, when Bird [31] developed a simple,
rapid and cheap methodological approach to detecting ACF
[25, 31]. In the last decade, additional biomarkers of colon
carcinogenesis have been identiﬁed, such as dark ACF [32],
ﬂat ACF [33], dysplastic ACF [34], MDF [30], and β-catenin
accumulated crypts (BCAC) [35]. Their characteristics and
application in short-term studies are brieﬂy described.
4.1. ACF. ACF are the ﬁrst lesions in the development of
CC that can be identiﬁed microscopically on the surface
of the whole mount colon mucosa after methylene blue
staining. They have been identiﬁed in carcinogen treated
rodents [25,31]andinhumansathighriskofdevelopingCC
(personal or familial history) [36, 37]. A number of studies
in rodents and humans, including molecular analysis, have
shown that ACF are lesions that are a valuable intermediate
biomarker in the development of colon carcinogenesis [38].
ACF have to date been used as an endpoint in identifying
and assessing the preventive or promotional role of natural
and pharmacological compounds, as well as dietary and
environmental factors, in the process of colon carcinogenesis
[4, 5].
An increasing number of studies have demonstrated
that ACF in both animals and humans are a heterogeneous
group of lesions containing multiple genetic, epigenetic,
and phenotypic alterations [37–40]. Histologically, ACF
exhibit variable features, ranging from mild atypia to
severe dysplasia. Most ACF show a hyperplastic character,
while only a small subgroup of ACF has been found to
contain intraepithelial neoplasia (such as severe dysplasia,
microadenoma, or carcinomainsitu). Ithasbeen shown that
ACFwithhyperplasiapossessdiﬀerentgeneticandepigenetic
alterations than ACF with dysplasia, and some studies have
suggested that ACF possessing hyperplastic feature may not
be directly related to tumorigenesis [27, 28]. However, there
are reports suggesting that some ACF possessing hyperplasic
features may progress to ACF with dysplasia [40, 41].
Nevertheless, ACF are useful biomarkers for the screen-
ing of compounds for their chemopreventive activities [5,
42]. When using ACF as biomarkers, it is important to
take into consideration that ACF are a heterogeneous group
of lesions. The total number of ACF may be considered
to be a valid biomarker only at a very early stage of
carcinogenesis, while, in subsequent weeks, ACF with higher
crypt multiplicities (more than 4 crypts) are considered4 Journal of Biomedicine and Biotechnology
a more speciﬁc biomarker than the total number of ACF. In
more advanced stages of colon carcinogenesis, ACF may not
be a reliable intermediate biomarker of colon carcinogenesis
(explained in detail by Bird and Good [24]a n dR a j u[ 42]).
It is also important to mention that ACF are not equally
distributed among the proximal, middle, or distal colon. The
majority of ACF develop in the middle and distal colon [43–
45], which needs tobe taken into account whenusing ACF as
biomarkers (comprehensively discussed by Bird [24, 25]a n d
Raju [42].
4.2. Subgroup of ACF with Dysplastic Features (Dark, Flat,
and Dysplastic ACF). Since dysplasia is widely accepted as an
indication of an increased risk of progression to cancer, it has
been suggested that dysplastic crypts may be more directly
associated with tumorigenesis than ACF [27]. Dysplastic
ACF have recently been identiﬁed by various investigators
using diﬀerent approaches. Ochiai et al. [34] developed
ad i ﬀerential staining method to identify dysplastic ACF,
while identiﬁcation of ﬂat ACF [33] and dark ACF [32]
were based on the surface morphology of ACF. However,
all these lesions have been observed as subgroups of ACF
with thicker epithelial lining, compressed luminal openings
and mildly enlarged crypts, which were not elevated from
surrounding epithelium. Histologically, all these subgroups
of ACF have possessed dysplastic features with absent or
scarce mucin production and have shown cytoplasmic and
nuclear accumulation of β-catenin [32–34]. Based on a
description of surface morphology (except the description
of staining intensity) and histological characteristics, it is
likely that ﬂat, dark, and dysplastic ACF may represent the
same group of ACF with dysplastic features. If each of these
lesions represents a diﬀerent subgroup of dysplastic ACF,
their use as biomarkers would probably be questionable or
confusing. Further investigations and determination of their
relations are certainly needed before they can be used as
biomarkers.
4.3. MDF. MDF are identiﬁed on the mucosal surface of
unsectioned colon after staining with high-iron diamine
alcian blue (HID-AB), which visualizes crypts with mucous
production [30]. Identiﬁcation of MDF is based on a scarce
or absent production of mucous, which is a common feature
of severe dysplasia. In contrast to ACF, which are histologi-
cally heterogenous, MDF are composed of dysplasic crypts,
which display frequent genetic and epigenetic alterations
observed also in colon cancer [46–49]. It has been shown
that MDF appear 7 weeks after carcinogen administration
and their number and multiplicity increases with time.
MDF have been demonstrated as a potential biomarker
for evaluation of the chemopreventive eﬀects of natural or
pharmacological compounds in colon carcinogenesis [50].
SincefewstudieshaveevaluatedMDFasabiomarker,further
investigations are needed to evaluate their role in colon
carcinogenesis.
4.4. BCAC. In contrast to ACF and MDF, which can be iden-
tiﬁed on the surface of the whole mount colon, identiﬁcation
Table 1: Nomenclature of colorectal lesions according to their
morphological appearance on whole mount colon (low magniﬁca-
tion) or according to their histological characteristics identiﬁed in
embedded and stained colon sections under a high-magniﬁcation
microscope.
Morphological
description Histological description
Tumour Adenomas:
(i) polypoid (i) low-grade dysplasia
(ii) nonpolypoid
(ii) high-grade dysplasia
Adenocarcinomas:
(i) well, moderate, and poorly
diﬀerentiated adenocarcinomas
(ii) mucinous adenocarcinomas
(iii) signet-ring cell adenocarcinomas
(iv) solid or undiﬀerentiated carcinomas
ACF (methylene
blue) Intraepithelial lesions:
(i) “dysplastic” (i) hyperplastic
(ii) dark
(ii) dysplastic/intraepithelial
neoplasia/microadenoma/carcinoma
in situ
(iii) ﬂat
MDF (HID-AB) (a) BCAC (immunohistochemical
staining)
ACF,aberrantcryptfoci;BCAC,β-cateninaccumulatedcrypts;MDF,mucin
depleted foci; HID-AB, high-iron diamine alcian blue.
of BCAC is based on an immunohistochemical method
in sectioned colon [35]. BCAC are intraepithelial lesions
that accumulate β-catenin protein in the cytoplasm and
nucleus and harbor frequent β-catenin (Ctnnb1) mutations.
Histologically, BCAC shows dysplasia with reduced or absent
mucin production [35, 51].
Based on the assumption that mutations in the β-catenin
gene or accumulation of β-catenin are the necessary ﬁrst
step in rat colon carcinogenesis, crypts with increased β-
catenin expression have been proposed as a more relevant
biomarker of colon cancer than ACF [27, 28, 35, 51].
However, histological identiﬁcation and quantiﬁcation of
BCAC is relatively costly, tedious, and time consuming,
which limits the use of BCAC as a biomarker.
However, we do not know at present whether BCAC,
MDF, dark, ﬂat, and dysplastic ACF are related lesions.
The development of these dysplastic lesions is clearly
related to the early development of tumours. Histologically,
all these lesions show dysplasia with scarce or absent
production of mucin and accumulate β-catenin in the
cytoplasm and/or nucleus. Accordingly, it is possible that
all these lesions are only dysplastic subgroups of ACF,
which may predict tumour outcome better than ACF itself.
However, ﬁrst investigations suggest that this assumption
may not be correct, because these lesions may not overlap
completely [52, 53]. Further investigations are, therefore,
needed to elucidate their features, evaluate relations and
discrepancy among them and to identify the reason for
discrepancy.Journal of Biomedicine and Biotechnology 5
Hyperplastic
crypts
? Normal
mucosa Dysplastic crypts Adenoma
K-ras K-ras, β-catenin, Apc
β-catenin, cyclin D1, c-myc, c-fos,
c-jun, Akt, PPAR-δ, mmp-7, LMW
PTP, FAS, MAPK , iNOS, COX-2
TGFα,T G F β,
Mutations
Hyperplastic ACF ? Biomarkers Tumours
Carcinoma
Dysplastic ACF, ﬂat ACF,
dark ACF, MDF, BCAC
β-catenin, cyclin D1, c-myc, c-fos,
c-jun, Akt, PPAR-δ, mmp-7
LMW PTP, FAS, MAPK
K-ras, β-catenin, Apc, α-catenin
Cyclin D1,
PPAR-δ,
COX-2
↓expression TGFα,T G F β
↑expression
TGFα,T G F β , E-cadherin E-cadherin, Smad3,
Figure 1: Phenotypic, genetic, and epigenetic alterations involved in multistep development of colon carcinogenesis in the DMH/AOM rat
model.
5. Gene Mutationsin DMH/AOM Colon
Carcinogenesis
Colon carcinogenesis is a multistage process, involving
multiple genetic and epigenetic changes that provide tumour
cells with a selective advantage to expand their clones
[54]. The stepwise development of CRC from dysplastic
crypts, adenomas to carcinomas provides opportunities for
the investigation and identiﬁcation of molecular alterations
at various stages of tumour development [24, 25, 55].
Genes that are mutated at diﬀerent stages of colorectal
carcinogenesis in human sporadic CC have been found to be
also mutated in DMH/AOM-induced colon carcinogenesis
and are described and discussed below.
5.1. Apc/β-Catenin. Mutations in the tumour suppressor
gene, APC, are responsible for an inherited predisposition
to colon cancer, FAP. APC mutations are also believed to
be the earliest events in the formation of sporadic colon
adenomas [54]. They have been identiﬁed in up to 80%
of sporadic colon tumours in humans [56]. The most
common APC mutation in human colon adenomas is APC
loss of heterozygosity (LOH), which causes truncation of
the protein and its inactivation. It is believed that the
main function of APC is the regulation of free β-catenin
in concert with glycogen synthase kinase 3β (GSK-3β)a n d
other proteins [54, 57]. It has been found that half of human
colon tumours with intact APC protein have a mutation in
the β-catenin gene [26].
Apc mutations have also been identiﬁed in colorectal
epithelial lesions in the DMH/AOM rat model, albeit to a
lesser degree and in a diﬀerent region from that observed
in humans [58]. In DMH/AOM-treated rats, up to 33% of
colon tumours harbour Apc mutations. These Apc mutations
havefrequentlybeenfoundlocatedupstreamfromtheregion
corresponding to the human APC mutation cluster region
(nt 3,186–3,810; nt 3078 and 3835 in exon 15). They have
mostly been missense or truncated point mutations (G to
Aa n dCt oTt r a n s i t i o n )[ 58–60]. A deletion of the region
containing the Apc gene has recently been found in one out
of ten tumours, suggesting that LOH may also be involved in
inactivation of Apc in this model [61].
In the DMH/AOM rat model, β-catenin mutations are a
more frequent event than Apc mutations, occurring in up to
77% of tumours (Table 2). They are mainly point mutations
(G to A transitions) localized in the GSK-3β phosphory-
lation consensus motif, which result in the inhibition of
GSK3 β-dependent phosphorylation of β-catenin. However,
Apc mutations or mutations in β-catenin have only been
observed in the DMH/AOM rat model and in human CC in
neoplastic/dysplastic lesions, that is, microscopic dysplastic
epithelial lesions, adenomas, and adenocarcinomas (shown
in Table 2) but not in hyperplastic lesions [35, 48, 58, 59, 62,
63].
5.2. K-Ras. The K-RAS gene encodes membrane bound
protein with intrinsic GTPase activity, which is involved in
the regulation of a number of important normal cellular
functions, including proliferation, diﬀerentiation, and apop-
tosis. Single point mutations at speciﬁc sites within ras genes
activate their oncogenic potential [64]. K-RAS mutations
have been observed with various frequencies (∼40%–50%)6 Journal of Biomedicine and Biotechnology
in human colorectal neoplastic lesions, as well as ACF with
hyperplastic epithelium. It has been reported that K-RAS is
mutated in fewer than 10% of small adenomas (less than
1cm in size), in about 50% of large adenomas (larger than
1cm) and in approximately 50% of carcinomas [56].
In DMH/AOM rat colon carcinogenesis, mutations in
the K-ras gene are point mutations (G to A transitions),
observed mostly in codon 12, rarely in codon 13 or 59. The
frequency of K-ras mutations in rat colon carcinogenesis has
been found to be variable, particularly in studies without
a description of the histological features or size of the
analyzed tumours [65–68]. Nevertheless, some studies have
demonstrated that K-ras mutations are less frequent in small
adenomas (on average ∼16%), while more frequent in large
adenocarcinomas (∼53%) [62, 69]. On the basis of those
studies, it appears that K-ras mutations in the DMH/AOM
rat model are as frequent as in human colon carcinogenesis.
As in humans, a K-ras mutation has been observed more
frequently in ACF with hyperplastic epithelium than in ACF
with dysplastic features [40, 62, 70, 71]. The mutation of
K-ras may thus be involved in the formation of the ACF
lesion and promotion of lesion growth but is probably not
essential. The fact that K-RAS mutation is frequently and
APC mutation very rarely observed in ACF in humans has
triggered debate about the role of K-RAS mutation in colon
carcinogenesis (discussed by Pretlow [37]).
5.3. p53. Although aberration of the tumour suppressor
P53 is a very common genetic lesion identiﬁed in human
carcinomas, no mutations in the p53 gene in DMH/AOM rat
colon carcinogenesis have been found by the single-strand
conformation polymorphism method, direct sequencing or
immunohistochemical analysis [59, 66, 72, 73]. Mutations
in the p53 gene have been investigated in regions (exon 5–
7) corresponding to the most commonly mutated regions
in human colon cancer (exon 5–8) [59]. It is interesting
that positive reactivity for p53 in ACF (27/65; 42%) and
adenocarcinomas (6/8; 25%) by immunohistochemically
was one of the ﬁrst reported alterations in ACF [74].
5.4. Genomic Instability. Two types of genomic instability
have been found in human colon cancer, that is, microsatel-
lite instability (MSI) and chromosomal instability (CIN).
MSI leads to an increase in the rate of subtle DNA changes
whereas CIN enhances the rate at which gross chromosomal
c h a n g e so c c u rd u r i n gc e l ld i v i s i o n ,s u c ha sc h r o m o s o m e
breaks, duplication, rearrangements, and deletions such as
LOH on varies sites in the genome [75].
In the DMH/AOM model, one or two chromosomal
aberrations (ampliﬁcation or deletion from 66 to 2135kb
in length) were found in 4/10 of tumours using a-CGH
analysis. In one case, even a LOH of the Apc gene on
chromosome 18 was found [61]. On the other hand, an
investigation based on RAPD analysis with 21 random
primers (GC rich) detected small alterations in the genome
in 100% of analyzed tumours (16/16) and even in 70%
of ACF (7/10) [67]. When tumours were analyzed on MSI
using 10 diﬀerent microsatellite DNA markers, it was found
that 29% of colonic tumours (13/45) showed MSI in at
least one locus and 15% of tumours (7/45) showed MSI at
multiple loci (MSI-high tumours) [76]. Using a PCR-based
approach with 6 DNA markers, MSI was reported in 21%
of tumours (4/20 adenomas and 2/8 carcinomas), mostly as
single-microsatellite change (insertion or deletion), and only
one tumour showed instability at three loci [67].
These results suggest that genomic instability is an
important molecular event in DMH induced colon carcino-
genesis. It seems that, unlike in human colon cancer, chro-
mosomal alterations in this model are relatively infrequent.
Much more frequent events in the DMH/AOM model are
small alterations in the genome that are involved in the
very early stages of colon carcinogenesis. Single nucleotide
changes, which have been found to be responsible for Apc,
β-catenin and K-ras mutations, are apparently widespread
and very frequent alterations in the genome of this model.
This carcinogen generates the methylated DNA adducts O6-
methylguanine, which, if not repaired, may mispair with
thymidine during DNA replication, resulting in a G:C to A:T
transition.
6. AlteredExpressionin DMH/AOM Colon
Carcinogenesis
Not only mutations but also many of the cellular and
molecular defects found in human colon carcinogenesis have
also been observed in DMH/AOM rat colon carcinogenesis.
These alterations have been found to be involved in various
pathways, such as the Wnt pathway, K-ras pathway, tumour
growth factor β (TGFβ) signaling pathway, and inﬂamma-
tory related process, which play important role in colon
cancer.
6.1. Wnt Pathway. The Wnt pathway has been implicated as
a crucial step in the initiation and development of colonic
tumorigenesis. In the absence of the extracellular Wnt signal,
free β-catenin is bound to the APC-axin-conductin-GSK3β
complex. Phosphorylation of β-catenin by this complex
marks it for ubiquitination and subsequent proteolytic
degradation by the proteasome. When APC or β-catenin is
mutated, β-catenin cannot be degraded but accumulates in
the cytoplasm and translocates into the nucleus, where it
binds to T-cell factor (TCF) and activates the Wnt target
genes [80–82].
In normal colon epithelial cells, β-catenin is highly
expressed in the cell membrane and not detected in the
cytoplasm or nucleus of cells [63]. In all dysplastic colorectal
epithelial lesions (dysplastic ACF, dark ACF, ﬂat ACF,
BCAC, MDF, adenomas, and adenocarcinomas), but not
in hyperplastic lesions, β-catenin expression is found to be
increased in the cytosol and nucleus [14, 77, 83]. Aberrant
expression of β-catenin has been associated with mutations
in Apc or β-catenin, but has also been present in lesions
without either Apc or β-catenin mutations [68], suggesting
that aberrant expression of β-catenin may be the result
of altered expression of one of the many proteins with
which β-catenin interacts, such as axin, conductin, or E-
cadherin [82]. In fact, inactivation of E-cadherin, whichJournal of Biomedicine and Biotechnology 7
Table 2: Frequencies of gene mutations found in biomarkers and diﬀerent stages of colon carcinogenesis in the DMH/AOM rat model.
Gene ACF/MDF (n) Histologic diagnosis (n) Tumours (n)A d e n o m a s ( n) Carcinomas (n) Carcinogen Ref.
Apc 0% ACF (66) — 14.3% (27) (17) (10) AOM [58]
— 22.2% dysplasia (18) — — — DMH [59]
15.4% AC (13)
— — 8.8% (57) — — DMH [60]
0% ACF (24) — 30.4% (23) 33.3% (12), 27.3% (11) DMH [48]
25% MDF (24)
β-catenin — — — — 75% (8) AOM [63]
15.4% ACF (13) 0% hyperplasia (10) 68.8% (32) 33% (6) 77% (26) AOM [62]
66% dysplasia (3)
20% ACF (15) 67% BCAC (15) — — — AOM [35]
— — 32.4% (68) — — AOM [68]
— — 37% (119) — — DMH [60]
7% ACF (27) — 40% (15) — — DMH [46]
25% MDF (28)
K-ras — — — — 66% (44) DMH [69]
32% ACF (19) — — — AC? AOM [70]
7.4% ACF (27) — 22% (50) 4.3% (23), 37% (27) AOM [65]
— — — — 60% DMHAOM [66]
53.8% ACF (13) 70% hyperplasia (10) 25% (28) 0% (2) small 8% (12) small AOM [77]
0% dysplasia (3) 43% (14) large
— — 16.7% (30) 9% (22) 37.5% (8) AOM [67]
— — 58% (43) 60% (10) 58% (33) DMH [78]
— — 16.7% (84) — — AOM [68]
27% ACF (6/22) — — — — AOM [79]
100% ACF (14) — 5.5% (18) 11% (9) small 0% (9) small DMH [47]
23% MDF (13)
P53 — — — — 0% (20) AOM [73]
— — — — 0% (10) MAM [72]
— 0% (31) — — — DMH [59]
Number in parenthesis denotes the total number of colon lesions analyzed. MSI, microsatellite instability; ACF, aberrant crypt foci; MDF, mucin depleted
foci; BCAC, β-catenin accumulated crypts; AC, adenocarcinoma in situ; —: not reported.
is normally bound with β-catenin and α-catenin into the
intercellular adhesion complex of epithelial cells and is a
negative regulator of colonic epithelial cell proliferation,
has already been described in human colon cancer and
in ACF of AOM treated rats [84]. Loss of the region
containing the α-catenin gene has also been found in
adenocarcinomas of this model [61]. Recent investigations
of the Wnt pathway have shown that activation and/or
downstream stimulation of the transcriptional activity of β-
catenin can be aﬀected by various signaling pathways and
factors, such as the mTOR signaling pathway and FOXO
proteins [81]. Aberrant expression of β-catenin, which is
frequently observed in the DMH/AOM model, therefore
oﬀers an opportunity to elucidate mechanisms involved in
β-catenin overexpression and to identify its downstream
targets in colon carcinogenesis. Well-known downstream
targets of APC/β-catenin/Tcf-4 mediated transcriptional
activation in colorectalneoplasia include genes such as cyclin
D1, c-myc, which have important roles in proliferation,
apoptosis, and cell-cycle progression and are responsible for
tumour formation [82]. Cyclin D1 and c-myc have been
found to be overexpressed in several stages of DMH/AOM
induced rat colon carcinogenesis [84, 85]. In one study,
an inverse correlation between increased Apc expression
level and decreased c-myc mRNA expression was reported
[86]. Overexpression of β-catenin has been found to be
correlated with increased expression of mmp-7, the protein
responsible for loss of cell adhesion and separation leading
to further unlimited cell growth [32]. A mutation in β-
catenin has been found to have no correlation with COX-
2 expression [68]. PPAR-δ, a target of the Wnt or K-ras
pathway that may function as an integrator of transcription
repression and nuclear receptor signaling [87] and has been
found to be elevated in DMH/AOM-induced adenomas and
adenocarcinomas (10/10) [88].
6.2. K-Ras Pathway. Mutations in the K-ras gene are respon-
sible for activation of the K-ras pathway, which is implicated
in colon carcinogenesis in humans and rats [14, 64]. In
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increased expression of Akt, a downstream target of the K-
ras pathway, has been found [89]. Akt plays an important
role in the PI3K/Akt pathway, which is implicated in a
variety of cellular processes, such as glucose metabolism, cell
proliferation, apoptosis, transcription, and cell migration.
PI3K/Akt promotes cyclin D1, which has been found to
be overexpressed in tumours with a K-ras mutation [68].
In addition, activation of the MEK/MAPK/ERK pathway,
another downstream K-ras signaling, has been found in
tumours without K-ras mutation. Activation of this pathway
has been associated with overexpression of c-erbB-2 recep-
tors and decreased expression of GTPase activating protein
(GAP), resulting in constitutive activation of normal K-ras
protein. However, it has been found that in tumours with
constitutively activated nonmutated K-ras, protein cyclin D1
expression was not increased. K-ras gene mutation and/or
protein activation increased COX-2 expression in tumours
[68].
The importance of the K-ras pathway in colon carcino-
genesis and possible therapeutic targets in this pathway are
described elsewhere [13, 64]. EGFR or P-tyr showed no
altered expression or distribution between ACF and normal
colonic mucosa by immunostaining [90].
6.3. TGFβ Pathway. Transforming growth factor alpha and
beta(TGFαandTGFβ)havebeenimplicatedinDMH/AOM-
induced colon carcinogenesis. TGFβ and TGFα expression
has been found to be reduced in ACF with hyperplasia or
dysplasia [24, 90]b u tT G F β1 enhanced in colonic tumours
[24],adenomasoradenocarcinomas(10/10)whenexamined
byimmunohistochemistryandNorthernanalysis[91].TGFβ
has been found to have a dual role. In normal cells, it stops
the cell cycle at the G1 stage, to stop proliferation, induce
diﬀerentiation or promote apoptosis and thus exerts tumour
suppressiveeﬀects.Incancercells,italsomodulatesprocesses
such as cell invasion, immune regulation, and microenvi-
ronment modiﬁcation that cancer cells may exploit to their
advantage [92]. In adenocarcinomas of the DMH/AOM
rat model, increased expression of TGF β1 (Tgfb1), their
receptors(Tgfrb1andTgfrb2),andreceptor-activatedSmads
(Smad2 and Smad4) has been found, while expression of
Smad3wasdownregulated[61].IthasbeenfoundthatTGFβ
and COX-2 were concurrently overexpressed in the same
colonic neoplastic lesions in AOM-treated rats, suggesting
that COX-2 expression in AOM-induced colonic tumour
could, in part, be due to the overexpression of TGFβ [91].
6.4. Other. Inﬂammation-related processes have also been
shown to be involved in the development of both human
and DMH/AOM-induced colon carcinogenesis [14, 93].
Increased expression of iNOS and COX-2 in epithelial cells
havefrequentlybeenobservedinDMH/AOM-inducedcolon
adenocarcinomas, adenomas, and ACF with dysplasia but
no detectable changes in the epithelial expression of these
proteinsinACFwithhyperplasiahasbeenfound[62,84,94].
COX-2, as well as iNOS enzymes, have been recognized as a
promising target for colon cancer prevention. Consequently,
many novel COX-2 inhibitors and NO inhibitors have been
considered to be chemopreventive agents on DMH/AOM-
induced colon carcinogenesis [95, 96]. The role of iNOS
and COX-2 in DMH/AOM-induced colon carcinogenesis
and its involvement in diﬀerent pathways of carcinogenesis
is excellently described by Takahashi and Wakabayashi [14].
In colon adenocarcinomas of the DMH/AOM rat model,
many other pathways such as those related to cell cycle,
RNA and protein metabolism, as well as pathways related
to extracellular matrix remodeling, inﬂammatory processes
and fatty acid oxidation, have been found to be upregulated
[61]. Fatty acid synthase (FAS) has been found to be over-
expressed in a variety of human cancers, including in ACF
o fh u m a nC C[ 97] and in AOM-treated rats in large ACF
with dysplastic epithelium [98]. It appears that FAS plays
an important role in the growth and survival of cancer cells,
because it is implicated in increased endogenous lipogenesis
of cancer cells. FAS inhibitors have been shown to decrease
cellproliferationandinduceapoptosisincancercelllinesand
have been suggested as a potential target of chemoprevention
in colon cancer [98].
Increased expression of the low molecular weight protein
tyrosine phosphatase (LMW-PTP), one of phosphotyro-
sine protein phosphatases involved in modulation of cell
phosphorylation, which plays a role in the production of
signals necessary for various cellular events, such as growth,
migration, and invasion of normal and malignant cells, has
been found in adenocarcinomas of DMH-treated rats and
human colon tumours [99].
A comprehensive study on gene expression proﬁle and
genomic alteration in DMH-induced colonic tumours in
rats was recently performed, which conﬁrmed the afore-
mentionedmolecularalterationsincoloncarcinogenesisand
revealed other pathways implicated in tumour development
that are also documented in human colon tumours [61].
This further demonstrates that the DMH/AOM rat model
is a valuable tool for studying the molecular mechanisms
involved in colon carcinogenesis and oﬀers an excellent
opportunity for evaluation of the eﬀect of chemopreventive
agents on CC development. Since DMH/AOM adminis-
tration has been shown to aﬀect oxidative status in the
circulation [100] and diﬀerent tissues of rats, such as heart
[101], liver [102], and small and large bowel [103], this
model has also been used for an evaluation of antioxidant
activities of natural or pharmacological compounds and
their involvement in colon carcinogenesis [104–106]. This
model thus oﬀers an opportunity to study and assess many
therapeutic targets involved in the CC process.
7. DistalandProximalColon Carcinogenesis
It has been found that proximal colonic neoplasms in
humans have distinct characteristics in terms of histology
and molecular genetics. They are generally less diﬀerentiated
and have a higher propensity for microsatellite instability
than distal ones [88]. According to our experience, the
majority of colon tumours in the DMH/AOM rat model
are located in the distal colon, while are less frequent in
the proximal colon. Histologically, tumours in the distalJournal of Biomedicine and Biotechnology 9
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Figure 2: Signaling pathways involved in the development of colon carcinogenesis in the DMH/AOM rat model.
colon are mostly adenomas and well or moderately diﬀeren-
tiated adenocarcinomas; in the proximal colon, tumours are
mostly poorly diﬀerentiated, mucinous, or signet-ring cell
adenocarcinomas. Similar observations have been reported
by other investigators [43, 107]. In addition, ACF density
is signiﬁcantly and progressively higher from the proximal
colon towards the distal, being the highest in the middle
and distal colon, which is in accordance with the location
of adenomas and carcinomas [43–45]. Observed diﬀerences
in the histological characteristics of colorectal epithelial
lesions between the distal and the proximal colon in rats
support the assumption of two distinct pathways in colon
carcinogenesis in the DMH/AOM rat model. It is believed
thatinthemiddleanddistalcolon,histogenesisfollowsACF-
adenoma-carcinoma sequences, while in the proximal colon,
poorly diﬀerentiated mucin-secreting carcinomas arise de
novo without an intermediate stage of colon carcinogenesis
[8, 43, 107]. Some studies have indicated that proximal
and distal tumours in the DMH/AOM rat model also have
distinct characteristics in terms of kinetic features [108],
sensitivity to carcinogens [24], chemotherapy [88], and K-
ras expression [69, 99]. In normal colon, mucosa diﬀerences
in apoptosis and expression of COX-2, PPAR-δ (higher in
distal than proximal colon) have also been reported [88].
All these observations are in line with reports on human
CC and suggest that proximal and distal colon tumours
are diﬀerent entities. However, whether proximal and distal
colon tumours in the DMH/AOM rat model have distinct
molecular features has not yet been investigated.
8. Limitationsof the DMH/AOM RatModel
DMH/AOM-induced models are often criticized due to their
exposure to DMH or AOM, which is believed not to be
a common event in humans. However, humans are often
exposed to hydrazine derivatives, because they are natural
components of mushrooms and tobacco, constituents of
herbicides, rocket fuel, and drugs [109]. The only diﬀerence
is that animal models are exposed to DMH/AOM in much
higher concentrations than humans. However, if we look at
the deﬁnition of an animal model, it can be seen that the
mode of induction is not a matter of debate or judgment
of a good animal model. By deﬁnition, an animal model is
“a living organism in which normative biology or behavior
can be studied, or in which a spontaneous or induced
pathological process can be investigated, and in which the
phenomenon in one or more respects resembles the same
phenomenon in humans or other species of animal” [110].
In the present paper, we have shown many similarities
and common features between human and DMH/AOM-
induced colon carcinogenesis, which demonstrate that the
DMH/AOM rat model is a valuable and suitable model
for assessment of dietary and chemopreventive agents or to
study the multistage development of colon cancer.
Nevertheless, as every animal model, the DMH/AOM
rat model also has limitations, which need to be taken
into account before conducting animal research. This
includesDMH/AOMmetabolicactivationandthemetastatic
potential of colonic adenocarcinomas. As has already been
mentioned, DMH/AOM are indirect carcinogens, which
need metabolic activation to become the active carcinogen
methyldiazonium ion. This process occurs in the liver
with the participation of various enzymes [15, 111]. If
the putative chemopreventive agent interferes with the
metabolic pathway of DMH/AOM, it may modify colon
carcinogenesis and aﬀect the results. It has already been
demonstrated that disulﬁram signiﬁcantly aﬀects colon
carcinogenesis, because it blocks the metabolism of AOM
due to its inhibitory activity on CYP2E1. CYP2E1 has been
unambiguously shown to be an important enzyme involved
inDMH/AOMmetabolism[111].Ithasalsobeenfoundthat
simultaneous administration of DMH/AOM and alcohol
inhibits colon carcinogenesis, probably due to suppression of
DMH/AOM activation in the liver [112, 113]. DMH/AOM-
induced colon carcinogenesis may thus be either inhibited
or enhanced by substances that are administered during the
initiationstage.Toavoidinterferencebetweenthecompound
and DMH/AOM activation, chemopreventive treatment can
begin after carcinogen administration, that is, during the
promotion or progression phase [5]. However, when a new
pharmacologicalcompoundistestedforitseﬀect,itisusually10 Journal of Biomedicine and Biotechnology
given in all the phases of colon carcinogenesis [5, 61]. If the
agent modiﬁes colon carcinogenesis at the initiation stage, it
is important to determine whether carcinogen metabolism is
being inﬂuenced and, if so, to identify the enzymes involved
[111].
In humans, lymphatic and hematogenous metastases are
common if colon tumours are not identiﬁed and removed
at an early stage. In contrast with humans, metastases to the
liver and lung are very uncommon in the DMH/AOM rat
model. Tumours that are capable of metastasis are almost
exclusively mucinous and signet ring cells carcinomas of
the proximal colon. Adenocarcinomas of the distal colon
have not been shown to metastasise. Metastases are generally
found in regional lymph nodes or on the peritoneal surface
[8].
9. Conclusion
The evidence from various studies summarized in this
paper demonstrate that the DMH/AOM rat model possesses
many characteristics found in human sporadic CC, which
makes it an important tool for studying diﬀerent aspects of
CC that cannot be eﬀectively studied in humans. Studies
on the DMH/AOM model allow monitoring the stepwise
development of CC under deﬁned experimental conditions.
They have already produced much important information
concerning the histology and biochemistry of tumour devel-
o p m e n t ,a sw e l la sa b o u tf a c t o r st h a tr e t a r do re n h a n c e
tumorigenesis.AlthoughtheDMH/AOMratmodeldoesnot
represent the complexity of the human disease and does not
replace studies with patient material, it is a valuable tool for
studying the molecular events of CC and for developing and
evaluating a variety of novel cancer chemopreventive agents
oremergingtherapeuticstrategiesthatarediﬃculttoaddress
in humans.
Finally, it should be recognized that animal models often
reﬂect only certain elements of pathophysiology and that the
quality of the answer strongly depends on the quality and
speciﬁcity of the experimental question asked.
References
[1] D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer
statistics, 2002,” CA Cancer Journal for Clinicians, vol. 55, no.
2, pp. 74–108, 2005.
[2] Y. S. Kim and J. A. Milner, “Dietary modulation of colon
cancer risk,” Journal of Nutrition, vol. 137, no. 11, pp. S2576–
S2579, 2007.
[ 3 ]A .E .T a m m a r i e l l oa n dJ .A .M i l n e r ,“ M o u s em o d e l sf o r
unraveling the importance of diet in colon cancer preven-
tion,” Journal of Nutritional Biochemistry,v o l .2 1 ,n o .2 ,p p .
77–88, 2010.
[4] D. E. Corpet and F. Pierre, “How good are rodent models of
carcinogenesisinpredictingeﬃcacyinhumans?Asystematic
review and meta-analysis of colon chemoprevention in rats,
mice and men,” European Journal of Cancer, vol. 41, no. 13,
pp. 1911–1922, 2005.
[5] M. J. Wargovich, A. Jimenez, K. McKee et al., “Eﬃcacy of
potentialchemopreventiveagentsonratcolonaberrantcrypt
formationandprogression,”Carcinogenesis,v ol.21,no .6,pp .
1149–1155, 2000.
[6] J. Heyer, K. Yang, M. Lipkin, W. Edelmann, and R. Kucher-
lapati, “Mouse models for colorectal cancer,” Oncogene, vol.
18, no. 38, pp. 5325–5333, 1999.
[ 7 ]A .M .F e m i aa n dG .C a d e r n i ,“ R o d e n tm o d e l so fc o l o n
carcinogenesis for the study of chemopreventive activity of
natural products,” Planta Medica, vol. 74, no. 13, pp. 1602–
1607, 2008.
[8] M. Perˇ se and A. Cerar, “The dimethylhydrazine induced
colorectal tumours in rat—experimental colorectal carcino-
genesis,” Radiology and Oncology, vol. 39, no. 1, pp. 61–87,
2005.
[9] R. P. Bird, “Aberrant crypt foci system to study cancer
preventive agents in the colon,” in Methods in Molecular
Medicine: Tumor Marker Protocols,M .H a n a u s e ka n dZ .
Walaszek, Eds., pp. 465–474, Humana Press, Totowa, NJ,
USA, 1998.
[10] H. Nakagama, M. Ochiai, T. Ubagai et al., “A rat colon cancer
model induced by 2-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine, PhIP,” Mutation Research, vol. 506-507, pp. 137–
144, 2002.
[11] A. Banerjee and P. Quirke, “Experimental models of colorec-
tal cancer,” Diseases of the Colon and Rectum, vol. 41, no. 4,
pp. 490–505, 1998.
[12] D.W.Rosenberg,C.Giardina,andT.Tanaka,“Mousemodels
for the study of colon carcinogenesis,” Carcinogenesis,vol. 30,
no. 2, pp. 183–196, 2009.
[13] J. Chen and XU. F. Huang, “The signal pathways in
azoxymethane-induced colon cancer and preventive impli-
cations,” Cancer Biology & Therapy, vol. 8, no. 14, pp. 1313–
1317, 2009.
[14] M. Takahashi and K. Wakabayashi, “Gene mutations and
altered gene expression in azoxymethane-induced colon
carcinogenesis in rodents,” Cancer Science, vol. 95, no. 6, pp.
475–480, 2004.
[15] E. S. Fiala and C. Stathopoulos, “Metabolism of methyla-
zoxymethanol acetate in the F344 rat and strain-2 guinea
pig and its inhibition by pyrazole and disulﬁram,” Journal of
Cancer Research and Clinical Oncology, vol. 108, no. 1, pp.
129–134, 1984.
[16] H. P. Glauert and M. R. Bennink, “Metabolism of 1,2-
dimethylhydrazine by cultured rat colon epithelial cells,”
Nutrition and Cancer, vol. 5, no. 2, pp. 78–86, 1983.
[ 1 7 ]C .T .O r a v e c ,C .A .J o n e s ,a n dE .H u b e r m a n ,“ A c t i v a t i o no f
the colon carcinogen 1,2-dimethylhydrazine in a rat colon
cell-mediated mutagenesis assay,” Cancer Research, vol. 46,
no. 10, pp. 5068–5071, 1986.
[18] W. W. L. Chang, “Histogenesis of colon cancer in experimen-
tal animals,” Scandinavian Journal of Gastroenterology, vol.
19, supplement, pp. 27–43, 1984.
[19] T. Shirai, J. Nakanowatari, and Y. Kurata, “Diﬀerent dose-
response relationships in the induction of diﬀerent types
of colonic tumors in wistar rats by 1,2-dimethylhydrazine,”
Gann, The Japanese Journal of Cancer Research, vol. 74, no. 1,
pp. 21–27, 1983.
[20] Z. Veˇ ceri´ c and A. Cerar, “Comparison of Wistar vs. Fischer
ratintheincidenceof1,2-dimethylhydrazineinducedintesti-
nal tumors,” Radiology and Oncology, vol. 38, no. 3, pp. 227–
247, 2004.
[21] L. Breskvar and A. Cerar, “A role of gender in the occurrence
of dimethylhydrazine induced colorectal tumors in Wistar
rats,” Radiology and Oncology, vol. 31, no. 4, pp. 374–379,
1997.Journal of Biomedicine and Biotechnology 11
[22] T. F. McMahon, J. O. Peggins, M. M. Centra, and M. Weiner,
“Age-related changes in biotransformation of azoxymethane
and methylazoxymethanol in vitro,” Xenobiotica, vol. 20, no.
5, pp. 501–513, 1990.
[ 2 3 ]B .A .M a g n u s o n ,E .H .S o u t h ,J .H .E x o ne ta l . ,“ I n c r e a s e d
susceptibility of adult rats to azoxymethane-induced aber-
rant crypt foci,” Cancer Letters, vol. 161, no. 2, pp. 185–193,
2000.
[24] R.P.BirdandC.K.Good,“Thesigniﬁcanceofaberrantcrypt
foci in understanding the pathogenesis of colon cancer,”
Toxicology Letters, vol. 112-113, pp. 395–402, 2000.
[25] R. P. Bird, “Role of aberrant crypt foci in understanding the
pathogenesis of colon cancer,” Cancer Letters, vol. 93, no. 1,
pp. 55–71, 1995.
[26] T. Tanaka, “Colorectal carcinogenesis: review of human and
experimental animal studies,” Journal of Carcinogenesis, vol.
8, article 5, 2009.
[27] H. Mori, Y. Yamada, T. Kuno, and Y. Hirose, “Aberrant crypt
foci and β-catenin accumulated crypts; signiﬁcance and roles
for colorectal carcinogenesis,” Mutation Research, vol. 566,
no. 3, pp. 191–208, 2004.
[28] H. Mori, K. Hata, Y. Yamada, T. Kuno, and A. Hara, “Sig-
niﬁcance and role of early-lesions in experimental colorectal
carcinogenesis,” Chemico-Biological Interactions, vol. 155, no.
1-2, pp. 1–9, 2005.
[29] G. P. Boivin, K. Washington, K. Yang et al., “Pathology of
mouse models of intestinal cancer: consensus report and
recommendations,” Gastroenterology, vol. 124, no. 3, pp.
762–777, 2003.
[30] G. Caderni, A. P. Femia, A. Giannini et al., “Identiﬁca-
tion of mucin-depleted foci in the unsectioned colon of
azoxymethane-treated rats: correlation with carcinogenesis,”
Cancer Research, vol. 63, no. 10, pp. 2388–2392, 2003.
[31] R. P. Bird, “Observation and quantiﬁcation of aberrant
crypts in the murine colon treated with a colon carcinogen:
preliminary ﬁndings,” Cancer Letters, vol. 37, no. 2, pp. 147–
151, 1987.
[32] Q. Lu, BO. Jiang, C. Lin, and T. Shan, “Dark Aberrant Crypt
FociwithactivatedWntpathwayarerelatedtotumorigenesis
inthecolonofAOM-treatedrat,”JournalofExperimentaland
Clinical Cancer Research, vol. 27, no. 1, article 26, 2008.
[33] J. E. Paulsen, E. M. Løberg, H. B. ∅lstørn, H. Knutsen,
I. L. Steﬀensen, and J. Alexander, “Flat dysplastic aberrant
crypt foci are related to tumorigenesis in the colon of
azoxymethane-treated rat,” Cancer Research, vol. 65, no. 1,
pp. 121–129, 2005.
[34] M. Ochiai, M. Watanabe, M. Nakanishi, A. Taguchi, T. Sug-
imura, and H. Nakagama, “Diﬀerential staining of dysplastic
aberrant crypt foci in the colon facilitates prediction of
carcinogenic potentials of chemicals in rats,” Cancer Letters,
vol. 220, no. 1, pp. 67–74, 2005.
[35] Y. Yamada, N. Yoshimi, Y. Hirose et al., “Frequent β-catenin
gene mutations and accumulations of the protein in the
putative preneoplastic lesions lacking macroscopic aberrant
crypt foci appearance, in rat colon carcinogenesis,” Cancer
Research, vol. 60, no. 13, pp. 3323–3327, 2000.
[36] T. P. Pretlow, B. J. Barrow, W. S. Ashton et al., “Aber-
rant crypts: putative preneoplastic foci in human colonic
mucosa,” Cancer Research, vol. 51, no. 5, pp. 1564–1567,
1991.
[37] T. P. Pretlow and T. G. Pretlow, “Mutant KRAS in aberrant
crypt foci (ACF): initiation of colorectal cancer?” Biochimica
et Biophysica Acta, vol. 1756, no. 2, pp. 83–96, 2005.
[38] L. Cheng and M. D. Lai, “Aberrant crypt foci as microscopic
precursors of colorectal cancer,” World Journal of Gastroen-
terology, vol. 9, no. 12, pp. 2642–2649, 2003.
[39] T. P. Pretlow, M. A. O’Riordan, K. M. Spancake, and T.
G. Pretlow, “Two types of putative preneoplastic lesions
identiﬁed by hexosaminidase activity in whole-mounts of
colons from F344 rats treated with carcinogen,” American
Journal of Pathology, vol. 142, no. 6, pp. 1695–1700, 1993.
[40] K. Otori, K. Sugiyama, T. Hasebe, S. Fukushima, and H.
Esumi, “Emergence of adenomatous aberrant crypt foci
(ACF) from hyperplastic ACF with concomitant increase in
cell proliferation,” Cancer Research, vol. 55, no. 21, pp. 4743–
4746, 1995.
[41] E. A. McLellan, A. Medline, and R. P. Bird, “Sequential
analyses of the growth and morphological characteristics of
aberrant crypt foci: putative preneoplastic lesions,” Cancer
Research, vol. 51, no. 19, pp. 5270–5274, 1991.
[42] J. Raju, “Azoxymethane-induced rat aberrant crypt foci:
relevance in studying chemoprevention of colon cancer,”
World Journal of Gastroenterology, vol. 14, no. 43, pp. 6632–
6635, 2008.
[43] H. S. Park, R. A. Goodlad, and N. A. Wright, “The
incidence of aberrant crypt foci and colonic carcinoma
in dimethylhydrazine-treated rats varies in a site-speciﬁc
manner and depends on tumor histology,” Cancer Research,
vol. 57, no. 20, pp. 4507–4510, 1997.
[44] M. A. M. Rodrigues, L. A. G. Silva, D. M. F. Salvadori, J. L.
V .D eC a m a r g o ,a n dM .R .M o n t e n e g r o ,“ A b e r r a n tc r y p tf o c i
andcoloncancer:comparisonbetweenashort-andmedium-
term bioassay for colon carcinogenesis using dimethylhy-
drazine in Wistar rats,” Brazilian Journal of Medical and
Biological Research, vol. 35, no. 3, pp. 351–355, 2002.
[45] M. Ghirardi, R. Nascimbeni, V. Villanacci, M. G. Fontana,
E. Di Betta, and B. Salerni, “Azoxymethane-induced aberrant
crypt foci and colorectal tumors in F344 rats: sequential
analysis of growth,” European Surgical Research, vol. 31, no.
3, pp. 272–280, 1999.
[46] A.P.Femia,B.Bendinelli,A.Gianninietal.,“Mucin-depleted
foci have β-catenin gene mutations, altered expression of its
protein, and are dose-and time-dependent in the colon of
1,2-dimethylhydrazine-treated rats,” International Journal of
Cancer, vol. 116, no. 1, pp. 9–15, 2005.
[47] A.P. Femia, E.Tarquini, M.Salvadori et al., “K-rasmutations
and mucin proﬁle in preneoplastic lesions and colon tumors
induced in rats by 1,2-dimethylhydrazine,” International
Journal of Cancer, vol. 122, no. 1, pp. 117–123, 2008.
[48] A. P. Femia, P. Dolara, A. Giannini, M. Salvadori, A. Biggeri,
and G. Caderni, “Frequent mutation of Apc gene in rat colon
tumors and mucin-depleted foci, preneoplastic lesions in
experimental colon carcinogenesis,” Cancer Research, vol. 67,
no. 2, pp. 445–449, 2007.
[49] A. P. Femia, P. Dolara, C. Luceri, M. Salvadori, and G.
Caderni, “Mucin-depleted foci show strong activation of
inﬂammatory markers in 1,2-dimethylhydrazine-induced
carcinogenesis and are promoted by the inﬂammatory agent
sodium dextran sulfate,” International Journal of Cancer, vol.
125, no. 3, pp. 541–547, 2009.
[50] A. Pietro Femia, P. Dolara, and G. Caderni, “Mucin-depleted
foci (MDF) in the colon of rats treated with azoxymethane
(AOM) are useful biomakers for colon carcinogenesis,”
Carcinogenesis, vol. 25, no. 2, pp. 277–281, 2004.
[51] Y. Yamada, N. Yoshimi, Y. Hirose et al., “Sequential
analysis of morphological and biological properties of β-
catenin-accumulated crypts, provable premalignant lesions12 Journal of Biomedicine and Biotechnology
independent of aberrant crypt foci in rat colon carcinogene-
sis,” Cancer Research, vol. 61, no. 5, pp. 1874–1878, 2001.
[52] N. Yoshimi, T. Morioka, T. Kinjo et al., “Histological and
immunohistochemical observations of mucin-depleted foci
(MDF) stained with Alcian blue, in rat colon carcinogenesis
induced with 1,2-dimethylhydrazine dihydrochloride,” Can-
cer Science, vol. 95, no. 10, pp. 792–797, 2004.
[53] A. P. Femia, J. E. Paulsen, P. Dolara, J. Alexander, and G.
Caderni, “Correspondence between ﬂat aberrant crypt foci
and mucin-depleted foci in rodent colon carcinogenesis,”
Anticancer Research, vol. 28, no. 6 A, pp. 3771–3775, 2008.
[54] A. B. Sparks, P. J. Morin, B. Vogelstein, and K. W. Kinzler,
“Mutational analysis of the APC/β-catenin/Tcf pathway in
colorectal cancer,” Cancer Research, vol. 58, no. 6, pp. 1130–
1134, 1998.
[ 5 5 ]R .P .B i r d ,D .S a l o ,C .L a s k o ,a n dC .G o o d ,“ An o v e l
methodological approach to study the level of speciﬁc
protein and gene expression in aberrant crypt foci putative
preneoplastic colonic lesions by Western blotting and RT-
PCR,” Cancer Letters, vol. 116, no. 1, pp. 15–19, 1997.
[56] C. Liu and J. Crawford, “The gastrointestinal tract,” in
Robbins and Cotran Patologic Basis of Disease, V. Kumar, A.
Abbas, and N. Fausto, Eds., pp. 797–875, Elsevier Saunders,
2004.
[57] P. J. Morin, A. B. Sparks, V. Korinek et al., “Activation of
β-catenin-Tcf signaling in colon cancer by mutations in β-
catenin or APC,” Science, vol. 275, no. 5307, pp. 1787–1790,
1997.
[58] C. De Filippo, G. Caderni, M. Bazzicalupo et al., “Mutations
of the Apc gene in experimental colorectal carcinogenesis
induced by azoxymethane in F344 rats,” British Journal of
Cancer, vol. 77, no. 12, pp. 2148–2151, 1998.
[ 5 9 ]K .J .S o h n ,M .P u c h y r ,R .N .S a l o m o ne ta l . ,“ T h ee ﬀect of
dietary folate on Apc and p53 mutations in the dimethylhy-
drazine rat model of colorectal cancer,” Carcinogenesis, vol.
20, no. 12, pp. 2345–2350, 1999.
[60] C. A. Blum, T. Tanaka, X. Zhong et al., “Mutational
analysis of Ctnnb1 and Apc in tumors from rats given
1,2-dimethylhydrazine or 2-amino-3-methylimidazo[4,5-
f]quinoline:mutational’hotspots’andtherelativeexpression
of β-catenin andc-jun,”MolecularCarcinogenesis,vol.36,no.
4, pp. 195–203, 2003.
[61] A. P. Femia, C. Luceri, S. Toti, A. Giannini, P. Dolara, and G.
Caderni, “Gene expression proﬁle and genomic alterations in
colonic tumours induced by 1,2-dimethylhydrazine (DMH)
in rats,” BMC Cancer, vol. 10, article 194, 2010.
[62] M. Takahashi, M. Mutoh, T. Kawamori, T. Sugimura, and
K. Wakabayashi, “Altered expression of β-catenin, inducible
nitricoxidesynthaseandcyclooxygenase-2inazoxymethane-
induced ratcoloncarcinogenesis,”Carcinogenesis,vol.21,no.
7, pp. 1319–1327, 2000.
[63] M. Takahashi, K. Fukuda, T. Sugimura, and K. Wak-
abayashi, “β-catenin is frequently mutated and demonstrates
altered cellular location in azoxymethane-induced rat colon
tumors,” Cancer Research, vol. 58, no. 1, pp. 42–46, 1998.
[64] M. Hajd´ uch, S. Janˇ c´ ık, J. Dr´ abek, and D. Radzioch, “Clinical
relevance of KRAS in human cancers,” Journal of Biomedicine
and Biotechnology, vol. 2010, Article ID 150960, 2010.
[65] A.A.Vivona,B.Shpitz,A.Medlineetal.,“K-rasmutationsin
aberrant crypt foci, adenomas and adenocarcinomas during
azoxymethane-induced colon carcinogenesis,” Carcinogene-
sis, vol. 14, no. 9, pp. 1777–1781, 1993.
[66] S. H. Erdman, H. D. Wu, L. J. Hixson, D. J. Ahnen, and E. W.
Gerner, “Assessment of mutations in Ki-ras and p53 in colon
cancers from azoxymethane- and dimethylhydrazine-treated
rats,” Molecular Carcinogenesis, vol. 19, no. 2, pp. 137–144,
1997.
[67] C. Luceri, C. De Filippo, G. Caderni et al., “Detection of
somatic DNA alterations in azoxymethane-induced F344
rat colon tumors by random ampliﬁed polymorphic DNA
analysis,” Carcinogenesis, vol. 21, no. 9, pp. 1753–1756, 2000.
[68] M. Bissonnette, S. Khare, F. C. Von Lintig et al., “Muta-
tional and nonmutational activation of p21 in rat colonic
azoxymethane-induced tumors: eﬀects on mitogen-activated
protein kinase, cyclooxygenase-2, and cyclin D1,” Cancer
Research, vol. 60, no. 16, pp. 4602–4609, 2000.
[69] R. F. Jacoby, X. Llor, B. B. Teng, N. O. Davidson, and T.
A. Brasitus, “Mutations in the K-ras oncogene induced by
1,2-dimethylhydrazine in preneoplastic and neoplastic rat
colonic mucosa,” Journal of Clinical Investigation, vol. 87, no.
2, pp. 624–630, 1991.
[70] S.A.Stopera,L.C.Murphy,andR.P.Bird,“Evidenceforaras
gene mutation in azoxymethane-induced colonic aberrant
crypts in Sprague-Dawley rats: earliest recognizable precur-
sor lesions of experimental colon cancer,” Carcinogenesis, vol.
13, no. 11, pp. 2081–2085, 1992.
[71] M. Perse, V. Mlinaric, and A. Cerar, “Aberrant crypt foci
as biomarkers predictive of colorectal carcinoma,” Slovenian
Medical Journal, vol. 79, no. 6, pp. 499–506, 2010.
[72] N. Shivapurkar, K. J. Nikula, T. Tanaka, Z. C. Tang, and
O. Alabaster, “Absence of p53 gene mutations in rat colon
carcinomas induced through the synergistic interaction
between methylazoxymethanol and X-irradiation,” Cancer
Letters, vol. 113, no. 1-2, pp. 9–16, 1997.
[73] N. Shivapurkar, S. A. Belinsky, D. C. Wolf, Z. Tang, and
O. Alabaster, “Absence of p53 gene mutations in rat colon
carcinomas induced by azoxymethane,” Cancer Letters, vol.
96, no. 1, pp. 63–70, 1995.
[74] S. A. Stopera and R. P. Bird, “Immunohistochemical demon-
stration of mutant p53 tumour suppressor gene product in
aberrant crypt foci,” Cytobios, vol. 73, no. 293, pp. 73–88,
1993.
[75] F. A. Orlando, D. Tan, J. D. Baltodano et al., “Aberrant crypt
fociasprecursorsincolorectalcancerprogression,”Journalof
Surgical Oncology, vol. 98, no. 3, pp. 207–213, 2008.
[76] M. Ravnik-Glavac, A. Cerar, and D. Glavac, “Animal model
in the study of colorectal carcinogenesis,” Pﬂugers Archiv
European Journal of Physiology, vol. 440, no. 5, pp. R55–R57,
2000.
[77] M. Takahashi, S. Nakatsugi, T. Sugimura, and K. Wak-
abayashi, “Frequent mutations of the β-catenin gene in
mousecolontumorsinducedbyazoxymethane,”Carcinogen-
esis, vol. 21, no. 6, pp. 1117–1120, 2000.
[78] T. A. De Jong, S. A. Skinner, C. Malcontenti-Wilson et al.,
“Inhibition of rat colon tumors by sulindac and sulindac
sulfone is independent of K-ras (codon 12) mutation,”
American Journal of Physiology - Gastrointestinal and Liver
Physiology, vol. 278, no. 2, pp. G266–G272, 2000.
[79] Y. Kishimoto, T. Morisawa, A. Hosoda, G. Shiota, H.
Kawasaki, and J. Hasegawa, “Molecular changes in the
early stage of colon carcinogenesis in rats treated with
azoxymethane,” Journal of Experimental and Clinical Cancer
Research, vol. 21, no. 2, pp. 203–211, 2002.
[80] M. Bordonaro, “Modular Cre/lox system and genetic ther-
apeutics for colorectal cancer,” Journal of Biomedicine and
Biotechnology, vol. 2009, Article ID 358230, 2009.
[81] T. Jin, I. George Fantus, and J. Sun, “Wnt and beyond Wnt:
multiple mechanisms control the transcriptional property ofJournal of Biomedicine and Biotechnology 13
β-catenin,” CellularSignalling, vol. 20, no. 10, pp. 1697–1704,
2008.
[82] F. T. Kolligs, G. Bommer, and B. G¨ oke, “Wnt/beta-
catenin/Tcf signaling: a critical pathway in gastrointestinal
tumorigenesis,” Digestion, vol. 66, no. 3, pp. 131–144, 2002.
[ 8 3 ] .X i n gP e iH a o ,T .G .P r e t l o w ,J .S .R a o ,a n dT .P .P r e t l o w ,“ β-
cateninexpressionisalteredinhumancolonicaberrantcrypt
foci,” Cancer Research, vol. 61, no. 22, pp. 8085–8088, 2001.
[84] R. K. Wali, S. Khare, M. Tretiakova et al., “Ursodeoxycholic
acid and F-D inhibit aberrant crypt proliferation in the
rat azoxymethane model of colon cancer: roles of cyclin
D1 and E-cadherin,” Cancer Epidemiology Biomarkers and
Prevention, vol. 11, no. 12, pp. 1653–1662, 2002.
[85] K. Otori, K. Sugiyama, S. Fukushima, and H. Esumi,
“Expression of the cyclin D1 gene in rat colorectal aberrant
crypt foci and tumors induced by azoxymethane,” Cancer
Letters, vol. 140, no. 1-2, pp. 99–104, 1999.
[86] Y. Kishimoto, K. Yashima, T. Morisawa, G. Shiota, H.
Kawasaki, and J. Hasegawa, “Eﬀects of cyclooxygenase-2
inhibitor NS-398 on APC and c-myc expression in rat
colon carcinogenesis induced by azoxymethane,” Journal of
Gastroenterology, vol. 37, no. 3, pp. 186–193, 2002.
[87] O. Takayama, H. Yamamoto, B. Damdinsuren et al., “Expres-
sion of PPARδ in multistage carcinogenesis of the colorec-
tum: implications of malignant cancer morphology,” British
Journal of Cancer, vol. 95, no. 7, pp. 889–895, 2006.
[88] H. K. Roy, W. J. Karolski, and A. Ratashak, “Distal bowel
selectivity in the chemoprevention of experimental colon
carcinogenesis by the non-steroidal anti-inﬂammatory drug
nabumetone,” International Journal of Cancer,v o l .9 2 ,n o .4 ,
pp. 609–615, 2001.
[89] H. K. Roy, B. F. Olusola, D. L. Clemens et al., “AKT proto-
oncogene overexpression is an early event during sporadic
colon carcinogenesis,” Carcinogenesis, vol. 23, no. 1, pp. 201–
205, 2002.
[90] I. Thorup, “Histomorphological and immunohistochemical
characterization of colonic aberrant crypt foci in rats:
relationship to growth factor expression,” Carcinogenesis,vol.
18, no. 3, pp. 465–472, 1997.
[91] J. Shao, H. Sheng, R. Aramandla et al., “Coordinate regula-
tion of cyclooxygenase-2 and TGF-β1i nr e p l i c a t i o ne r r o r -
positive colon cancer and azoxymethane-induced rat colonic
tumors,” Carcinogenesis, vol. 20, no. 2, pp. 185–191, 1999.
[92] J. Massagu´ e, “TGFβ in Cancer,” Cell, vol. 134, no. 2, pp. 215–
230, 2008.
[93] E. Spisni, A.Strillacci, C.Griﬀoni, M.C. Valerii, G. Lazzarini,
and V. Tomasi, “RNAi-based strategies for cyclooxygenase-2
inhibition in cancer,” Journal of Biomedicine and Biotechnol-
ogy, vol. 2010, Article ID 828045, 2010.
[94] R. N. DuBois, A. Radhika, B. S. Reddy, and A. J. Entingh,
“Increasedcyclooxygenase-2levelsincarcinogen-inducedrat
colonic tumors,” Gastroenterology, vol. 110, no. 4, pp. 1259–
1262, 1996.
[95] M. Perˇ se, A. Zebic, and A. Cerar, “Rofecoxib does not inhibit
aberrant crypt foci formation but inhibits later steps in the
development of experimental colorectal cancer: rofecoxib
in experimental colon cancer,” Scandinavian Journal of
Gastroenterology, vol. 40, no. 1, pp. 61–67, 2005.
[96] T. Kawamori, M. Takahashi, K. Watanabe et al., “Suppression
of azoxymethane-induced colonic aberrant crypt foci by a
nitric oxide synthase inhibitor,” Cancer Letters, vol. 148, no.
1, pp. 33–37, 2000.
[97] K. E. Kearney, T. G. Pretlow, and T. P. Pretlow, “Increased
expression of fatty acid synthase in human aberrant crypt
foci: possible target for colorectal cancer prevention,” Inter-
national Journal of Cancer, vol. 125, no. 1, pp. 249–252, 2009.
[98] D. S. Y. Lau and M. C. Archer, “Fatty acid synthase is over-
expressed in large aberrant crypt foci in rats treated with
azoxymethane,” International Journal of Cancer, vol. 124, no.
11, pp. 2750–2753, 2009.
[99] R. Marzocchini, F. Malentacchi, M. Biagini et al., “The
expression of low molecular weight protein tyrosine phos-
phatase is up-regulated in 1,2-dimethylhydrazine-induced
colon tumours in rats,” International Journal of Cancer, vol.
122, no. 7, pp. 1675–1678, 2008.
[100] T. Devasena, V. P. Menon, and K. N. Rajasekharan, “Pre-
ventionof1,2-dimethylhydrazine-inducedcirculatoryoxida-
tive stress by bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-
3,5-dione during colon carcinogenesis,” Pharmacological
Reports, vol. 58, no. 2, pp. 229–235, 2006.
[101] M. Perˇ s e ,R .I n j a c ,B .ˇ Strukelj, and A. Cerar, “Eﬀects of high-
fat mixed-lipid diet and exercise on the antioxidant system in
skeletal and cardiac muscles of rats with colon carcinoma,”
Pharmacological Reports, vol. 61, no. 5, pp. 909–916, 2009.
[102] R. Injac, M. Perse, M. Cerne et al., “Protective eﬀects of
fullerenol C(OH) against doxorubicin-induced cardiotox-
icity and hepatotoxicity in rats with colorectal cancer,”
Biomaterials, vol. 30, no. 6, pp. 1184–1196, 2009.
[103] V. Sreedharan, K. K. Venkatachalam, and N. Namasivayam,
“Eﬀect of morin on tissue lipid peroxidation and antioxidant
status in 1, 2-dimethylhydrazine induced experimental colon
carcinogenesis,” Investigational New Drugs,v o l .2 7 ,n o .1 ,p p .
21–30, 2009.
[104] J. S. Giftson, S. Jayanthi, and N. Nalini, “Chemopreventive
eﬃcacy of gallic acid, an antioxidant and anticarcinogenic
polyphenol, against 1,2-dimethyl hydrazine induced rat
colon carcinogenesis,” Investigational New Drugs, vol. 28, no.
3, pp. 251–259, 2010.
[105] V. Manju, V. Balasubramaniyan, and N. Nalini, “Rat colonic
lipid peroxidation and antioxidant status: the eﬀects of
dietary luteolin on 1,2-dimethylhydrazine challenge,” Cellu-
lar and Molecular Biology Letters, vol. 10, no. 3, pp. 535–551,
2005.
[106] S. Samanta, V. Swamy, D. Suresh et al., “Protective eﬀects
of vanadium against DMH-induced genotoxicity and car-
cinogenesis in rat colon: removal of O-methylguanine
DNA adducts, p53 expression, inducible nitric oxide syn-
thase downregulation and apoptotic induction,” Mutation
Research, vol. 650, no. 2, pp. 123–131, 2008.
[107] J. P. Sunter, D. R. Appleton, N. A. Wright, and A. J. Watson,
“Pathological features of the colonic tumours induced in rats
by the administration of 1,2-dimethylhydrazine,” Virchows
Archiv B Cell Pathology, vol. 29, no. 1, pp. 211–223, 1978.
[108] T. J. McGarrity, L. P. Peiﬀe r ,a n dP .C .C o l o n y ,“ C e l l u l a r
proliferation in proximal and distal rat colon during 1,2-
dimethylhydrazine-induced carcinogenesis,” Gastroenterol-
ogy, vol. 95, no. 2, pp. 343–348, 1988.
[109] M. Gamberini, M. R. Cidade, L. A. Valotta, M. C. S.
Armelin, and L. C. C. Leite, “Contribution of hydrazines-
derived alkyl radicals to cytotoxicity and transformation
induced in normal c-myc-overexpressing mouse ﬁbroblasts,”
Carcinogenesis, vol. 19, no. 1, pp. 147–155, 1998.
[110] J. Hau, “Animal models,” in Handbook of Laboratory Animal
Sience: Animal Models, J. Hau and G. van Hoosier, Eds., pp.
1–9, CRC Press, Boca Raton, Fla, USA, 2003.
[111] O. S. Sohn, E. S. Fiala, S. P. Requeijo, J. H. Weisburger, and
F. J. Gonzalez, “Diﬀerential eﬀects of CYP2E1 status on the
metabolic activation of the colon carcinogens azoxymethane14 Journal of Biomedicine and Biotechnology
and methylazoxymethanol,” Cancer Research, vol. 61, no. 23,
pp. 8435–8440, 2001.
[112] M. Perˇ se and A. Cerar, “Dimethylhydrazine model is not
appropriate for evaluating eﬀect of ethanol on colorectal
cancer,” Revista Espanola de Enfermedades Digestivas, vol. 99,
no. 8, pp. 463–466, 2007.
[113] J. F. Noguera Aguilar and A. Cuadrado Garc´ ıa, “Ethanol
andcolicexperimentalcarcinogenesisEtanolycarcinog´ enesis
c´ olica experimental,” Revista Espanola de Enfermedades
Digestivas, vol. 99, no. 8, pp. 438–439, 2007.